AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01489397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocol laser endomicroscopy
Description: Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
Study NCT01489397 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Confocol laser endomicroscopy
Description: Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
Study NCT00436241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 iv on day 1 of each 2 week cycle
Study NCT00436241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-10 of each 2 week cycle
Study NCT02904889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay Active at Home
Description: Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
Study NCT02904889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Homecare professionals will get no training and their clients will receive usual homecare.
Study NCT04216966 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No intervention was given
Study NCT04216966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gracey Curette
Description: Lingual surface of tooth was debrided by Gracey Rigid curette
Study NCT04216966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: After Five
Description: Lingual surface of tooth was debrided by After Five Rigid curette
Study NCT04216966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini Five
Description: Lingual surface of tooth was debrided by Mini Five Rigid curette
Study NCT01848496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival displacement
Description: Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
Study NCT01848496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival displacement
Description: Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
Study NCT03363269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID1201
Study NCT03363269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ID1201
Study NCT04521660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
Study NCT00491764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
Study NCT02048709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0919
Description: Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
Study NCT03960619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping skills training
Description: We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
Study NCT00906282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
Study NCT00906282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
Study NCT03944343 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cereal based products
Description: The cereal products are made from common Swedish cereals.
Study NCT03944343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal based products
Description: The cereal products are made from common Swedish cereals.
Study NCT00491764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
Study NCT00491764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
Study NCT00491764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 56592
Description: Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
Study NCT00491764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: Terbinafine 250 mg QD for 12 weeks.
Study NCT00573703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Burch colposuspension
Description: Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
Study NCT00573703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturator tape procedure
Description: Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
Study NCT03357224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
Study NCT04566874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALIF
Description: Anterior Lumbar Interbody Fusion
Study NCT04566874 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ALIF
Description: Anterior Lumbar Interbody Fusion
Study NCT02294643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate
Study NCT02294643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Study NCT02294643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02294643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Study NCT02294643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02294643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Sarpogrelate)
Study NCT04671108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week
Study NCT04671108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)
Description: Daily disposable contact lens wear for 1 week
Study NCT04243343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention + Standard of care
Description: Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
Study NCT04243343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care prescribed home exercise program for treatment of plantar fasciosis.
Study NCT03644537 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthodontic intrusion
Description: 27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram).
Study NCT03425162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: patient-controlled analgesia (PCA) morphine
Study NCT03425162 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine Sulfate
Description: patient-controlled analgesia (PCA) morphine
Study NCT03425162 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Group P
Description: Group P:patient-controlled analgesia (PCA) morphine
Study NCT03425162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
Study NCT04181931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neo-TACE-HAIC+Surgery
Description: transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
Study NCT04181931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone
Description: hepatic resection remove the liver tumor and portal vein tumor thrombus
Study NCT02837237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.
Study NCT00436137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient mailing
Description: Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
Study NCT03264456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F] Fluciclovine PET/MRI
Description: \[18F\] fluciclovine PET/MRI
Study NCT03264456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] fluciclovine
Description: \[18F\] fluciclovine
Study NCT02784327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF110
Study NCT02078934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Gastric Plication
Description: Evaluate the efficacy of endoscopic suturing for weight loss
Study NCT03234816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.05 mcg /Kg/min
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Study NCT03234816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.1 mcg /Kg/min
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Study NCT03234816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.15 mcg /Kg/min
Description: Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
Study NCT00491764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 24 weeks.
Study NCT02675985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Early Intensive Physical therapy in the ICU
Study NCT02607930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/DTG/3TC
Description: 600/50/300 milligrams (mg) tablets administered orally, once daily
Study NCT03234816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mg Bupivacaine intra-thecal for spinal anesthesia
Study NCT02967237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (U300)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT02607930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally, once daily, without regard to food
Study NCT02607930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC Placebo
Description: Tablets administered orally, once daily
Study NCT02607930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablets administered orally, once daily
Study NCT00354887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
Study NCT00354887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 by vein Day 1 over 2 hours in 21 Day Cycle
Study NCT02110238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supartz
Description: Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
Study NCT02110238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Euflexxa
Description: Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
Study NCT04076878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mollii
Description: The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
Study NCT04403360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
Study NCT04403360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration by the surgeon
Description: Local infiltration of anesthetics at surgical site after skin incision
Study NCT03967301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Intervention: defined as probiotic consumption
Study NCT03967301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consumption. The placebo will be provided by the company that produces the probiotic.
Study NCT02123342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise programme plus SMS reminders
Description: Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
Study NCT02877134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 Subcutaneously.
Study NCT02877134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo Subcutaneously.
Study NCT02877134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive ustekinumab as per the dosing regimen.
Study NCT01146990 — intervention group
Intervention type: DRUG
Intervention: ASQ-3, Bayley III, Neurologic exam
Description: Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
Study NCT04261036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 1000 mg
Description: 1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
Study NCT04261036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills for 14 days post-op after an elective gynecological surgery.
Study NCT03515083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alive Cor Kardia mobile electrocardiogram monitor
Description: Mobile ECG monitor paired with smart phone application
Study NCT01500031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OffRoad Re-entry Catheter System
Description: Facilitate the placement and positioning of guidewires within the peripheral vasculature.
Study NCT02420522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.
Study NCT02420522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.
Study NCT03764943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advanced Recovery
Description: immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
Study NCT02506673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss, Cinema ProMED (audiovisual equipment)
Study NCT02506673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02420522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Magnetic Stimulation
Description: A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
Study NCT01414660 — intervention group
Intervention type: PROCEDURE
Intervention: transplantation
Description: transplantation of islet, kidney or liver
Study NCT03593096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT03593096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT00767962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: talc pleurodesis under medical thoracoscopy
Description: talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
Study NCT00767962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pleurodesis under video-assisted thoracoscopy surgery
Description: pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
Study NCT04337268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-Like Peptide 1
Description: Intravenous infusion (1.5 pmol/kg/min) for 60 min.
Study NCT04337268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Intravenous infusion for 60 min.
Study NCT02506673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT02506673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Conductance Monitor
Study NCT03965988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02506673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin Conductance Monitor
Study NCT01194037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant variant of interferon-alpha 2b
Description: SC, Weekly
Study NCT01194037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: SC Weekly
Study NCT03817229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education microlearning sessions
Description: mHealth education microlearning sessions
Study NCT03817229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education microlearning sessions
Description: mHealth education microlearning sessions
Study NCT03817229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated digital reminders
Description: reminders from electronic monitors based on texts or lights/chimes